1. A method for treating a human subject at risk of suffering from an intracranial aneurysm comprising administering to said human subject a therapeutically effective dose of an autophagy inhibitor, wherein the autophagy inhibitor is selected from the group consisting of wortmannin, chloroquine, clomipramine, 3-Methyladenine, Bafilomycin A1, Pepstatin A, and Pepstatin E-64-d, wherein the human subject carries a variant affecting the expression of a Thrombospondin Type 1 Domain Containing 1 (THSD1) gene.
|